phrykt

20/20 Biolabs, Inc. (AIDX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of AIDX were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No AIDX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AIDX short interest

Low short interest. 0.5% of AIDX shares are sold short: about 1 share in 186. Over the last 12 reports the number of shares short went up 216%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 57,001 AIDX shares were sold short, 0.5% of the shares outstanding, up 405.8% from the report before. At the average daily volume of 160,271 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.54%May 15Oct 303.15%

Days to cover

1.0May 15Oct 301.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202657,0010.54%+406%160,2711.0
Oct 15, 202611,2700.11%-75%131,7531.0
Sep 30, 202645,1670.43%-4%52,4721.0
Sep 15, 202646,8060.44%-50%58,9911.0
Aug 31, 202694,2800.89%-11%100,2401.0
Aug 14, 2026105,8411.00%-31%100,6971.1
Jul 31, 2026153,2931.44%-38%118,2741.3
Jul 15, 2026248,6472.34%+33%342,8001.0
Jun 30, 2026186,8631.76%-36%424,5081.0
Jun 15, 2026291,9902.75%+127%2.69M1.0
May 29, 2026128,7751.21%+613%1.13M1.0
May 15, 202618,0500.17%-45%70,7681.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

20/20 Biolabs company events

20/20 Biolabs filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (listing). The latest was on Sep 18, 2026.

  1. Sep 18, 2026VoteReported shareholder vote results. Filing
  2. Sep 10, 2026ListingAs previously disclosed, on July 17, 2026, 20/20 Biolabs, Inc. received a notification letter from The Nasdaq Stock Market LLC indicating that the Company was not in compliance with the $1.00 closing bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive… Filing
  3. Sep 2, 2026AnnouncementShared information with investors. Filing
  4. Aug 19, 2026VoteReported shareholder vote results. Filing
  5. Aug 17, 2026ResultsReleased financial results. Filing
  6. Aug 5, 2026AnnouncementShared information with investors. Filing
  7. Jul 22, 2026ListingThe Company received a written notification from The Nasdaq Stock Market LLC indicating that the Company was not in compliance with the $1.00 closing bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days from June 3, 2026 to July 16, 2026. Filing
  8. Jul 1, 2026AnnouncementShared information with investors. Filing
  9. May 26, 2026SharesChanged the rights of its shareholders. Filing
  10. May 20, 2026ResultsReleased financial results. Filing
  11. Apr 28, 2026AgreementAs previously disclosed, on November 17, 2025, 20/20 Biolabs, Inc. entered into a securities purchase agreement with Streeterville Capital, LLC, pursuant to which the Company agreed to offer and sell to Streeterville, in a private placement transaction, secured convertible promissory notes in the… Filing
  12. Apr 1, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

20/20 Biolabs financials

Famous investors that hold AIDX

1 of the 50 well-known investors we track reported holding AIDX in their latest 13F filing. The largest position is Ken Griffin's, worth $27.9K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202663,838$27.9K0.0%+175%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about 20/20 Biolabs, Inc. (AIDX) stock

Are AIDX insiders buying or selling?

No AIDX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in AIDX?

As of Oct 30, 2026, 57,001 AIDX shares were sold short, 0.5% of the shares outstanding, up 405.8% from the report before. At the average daily volume of 160,271 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold AIDX?

1 of the 50 well-known investors we track reported AIDX in their latest 13F filing, including Ken Griffin. The largest position is worth $27.9K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.